

EXHIBIT A

Materials Reviewed

1. Amy G. Egan, et al., *Pancreatic Safety of Incretin-Based Drugs—FDA and EMA Assessment*, N. Eng. J. Med. 794, 795 (Feb. 27, 2014).
2. Citizen's Petition: Docket No. FDA-2012-P-0404 (April 19, 2012).
3. FDA's response to the Citizen's Petition: Docket No. FDA-2012-P-0404 (March 25, 2014).
4. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes (March 14, 2013).
5. Labeling for incretin-based therapies, including Byetta (exenatide), Bydureon (exenatide extended release), Victoza (liraglutide), Januvia (sitagliptin), Janumet (sitagliptin and metformin), Onglyza (saxagliptin), Tradjenta (linagliptin), Nesina (alogliptin), Trulicity (dulaglutide), and Tanzeum (albiglutide).
6. National Institute of Diabetes and Digestive and Kidney Diseases Workshop on Pancreatitis, Diabetes, Pancreatic Cancer, June 12-13, 2013 (abstracts of presentations by FDA's Dr. Solomon Iyasu and Dr. Timothy Hummer).
7. FDA Staff Manual Guide (SMG 2126.3: Review of FDA-Related Articles and Speeches).
8. Relevant FDA regulations, guidance documents, standard operating procedures, and statements in the Federal Register.